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Aims Positron emission tomography–computed tomography (PET-CT) is a highly sensitive clinical molecular imaging modal-
ity to study atherosclerotic plaque biology. Therefore, we sought to develop a new PET tracer, targeting vascular cell




The anti-VCAM-1 nanobody (Nb) (cAbVCAM-1–5) was radiolabelled with Fluorine-18 (18F), with a radiochemical
purity of .98%. In vitro cell-binding studies showed specific binding of the tracer to VCAM-1 expressing cells. In vivo
PET/CT imaging of ApoE2/2 mice fed a Western diet or control mice was performed at 2h30 post-injection of [18F]-
FB-cAbVCAM-1–5 or 18F-control Nb. Additionally, plaque uptake in different aorta segments was evaluated ex vivo
based on extent of atherosclerosis. Atherosclerotic lesions in the aortic arch of ApoE2/2 mice, injected with [18F]-
FB-anti-VCAM-1 Nb, were successfully identified using PET/CT imaging, while background signal was observed in
the control groups. These results were confirmed by ex vivo analyses where uptake of [18F]-FB-cAbVCAM-1–5 in ath-
erosclerotic lesions was significantly higher compared with control groups. Moreover, uptake increased with the in-
creasing extent of atherosclerosis (Score 0: 0.68+ 0.10, Score 1: 1.18+ 0.36, Score 2: 1.49+ 0.37, Score 3:
1.48+ 0.38%ID/g, Spearman’s r2 ¼ 0.675, P, 0.0001). High lesion-to-heart, lesion-to-blood, and lesion-to-control
vessel ratios were obtained (12.4+0.4, 3.3+0.4, and 3.1+ 0.6, respectively).
Conclusion The [18F]-FB-anti-VCAM-1 Nb, cross-reactive for both mouse and human VCAM-1, allows non-invasive PET/CT
imaging of VCAM-1 expression in atherosclerotic plaques in a murine model and may represent an attractive tool
for imaging vulnerable atherosclerotic plaques in patients.
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Introduction
Many data support a crucial role of inflammation in the development
and progression of atherosclerosis.1,2 Moreover, inflammation is in-
volved in plaque destabilization and promotes thrombus formation.1
Indeed, post-mortem studies, related to acute coronary events,
reveal extensive infiltration of inflammatory cells in culprit lesions.3
Vascular cell adhesion molecule-1 (VCAM-1), expressed on endo-
thelial cells, plays an important role in the disease progression by at-
tracting inflammatory cells (monocytes and T-lymphocytes) to the
developing lesion.4 In advanced lesions, VCAM-1 is also expressed
at the level of neovessels and may reflect the ongoing inflammation
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within the plaque.5 These properties make VCAM-1 an attractive
target for the molecular imaging of inflammation in atherosclerosis.6
Nanobodies (Nbs) are the smallest antigen-binding fragments
(12–15 kDa) that are derived from heavy-chain-only antibodies nat-
urally occurring in camelids.7 Their small size, nanomolar-range af-
finities, high specificity, and fast blood clearance make them
appealing ligands for molecular imaging approaches8 and this has
been shown for several experimental disease models.9 – 16 More-
over, a Phase I clinical trial demonstrated the applicability of
Nb-based tracers in humans.17
Nuclear imaging techniques are the modalities of choice for mo-
lecular imaging because of their high sensitivity. We have recently
reported the use of a technetium-99 m (99mTc)-labelled
anti-VCAM-1 Nb, referred to as cAbVCAM-1–5, as strategy for
the detection of inflamed atherosclerotic plaque with single-photon
emission computed tomography (SPECT).10 Yet, positron emission
tomography (PET) is more appropriate for clinical use compared
with SPECT because of its superior spatial resolution (3–5 vs.
10–15 mm), higher sensitivity (0.8 vs. 0.001%), and more accurate
quantification.18 Despite the advantages of PET, only a few clinical
studies regarding molecular imaging of inflammation in atheroscler-
osis have been conducted. They are predominantly performed with
tracers, e.g. 18F-FDG,15 11C-PK11195,19 or 18F-FLT.20 However, ap-
proaches using 18F-FDG or 11C-PK11195 are limited to the imaging
of noncoronary atherosclerosis because of tracer uptake in the
myocardium.19,21,22 Therefore, the development of new robust
PET tracers for imaging of biological processes implicated in high-
risk atherosclerotic plaques is still warranted.
In the current study, our objective is to generate a PET analogue
of anti-VCAM-1 Nb for PET/CT imaging of atherosclerosis as a fur-
ther step to clinical translation. Specifically, we describe (i) the radi-
olabeling of cAbVCAM-1–5 with 18F, (ii) the assessment of the
functionality and specific targeting of this tracer, and (iii) in vivo





Nanobodies recognizing both mouse and human VCAM-1 homologues
have been described previously. Herein, a lead compound,
cAbVCAM-1–5, was selected as best candidate for further studies.10
N-Succinimidyl-4-[18F]fluorobenzoate ([18F]-SFB) synthesis consisted
of a three-step, one-pot reaction by solid-phase extraction (SPE) purifi-
cation as described previously.23 The [18F]-SFB synthesis was incorpo-
rated into a commercially available synthetic module (SynthERAw
module, IBA Molecular, Belgium). Coupling of dry [18F]-SFB with
cAbVCAM-1–5 Nb was performed in borate buffer (0.1 M, pH 8.5,
300 mL, 18.5 nmol Nb) for 20 min at room temperature, and the label-
ling mixture was purified using a PD-10 column (GE Healthcare,
Belgium). The radiochemical identity and purity were assessed by
size-exclusion chromatography (SEC, Superdex 75, 5/150 GL, GE
Healthcare, PBS 0.3 mL min21) and by reverse-phase high-performance
liquid chromatography (RP-HPLC). For the latter, a polystyrene divinyl-
benzene copolymer reversed-phase column (PLRP-S 300 A˚, 5 mm, 250/
4 mm, Agilent) was used applying the following gradient (A: 0.1% TFA in
water; B: 0.1% TFA in acetonitrile): 0–5 min 25% B, 5–7 min 25–34% B,
7–10 min 34–100% B, and 10–25 min 100% B at a flow rate of
1 mL min21. To evaluate the stability in vitro, [18F]FB-cAbVCAM-1–5
Nb was incubated in phosphate-buffered saline (PBS) or human serum for
3 h and analysed by RP-HPLC or SEC. Additionally, urine and serum samples
were obtained after intravenous injection of [18F]FB-cAbVCAM-1–5 and
analysed by SEC.
In vitro assessment of functionality and
specificity
The functionality of [18F]FB-anti-VCAM-1 Nb was assessed by cell-
binding studies using the mouse endothelial cell line bEND5 (ECACC).
These cells were stimulated with 10 ng/mL tumour necrosis factor-
alpha (TNF-a) for 18 h to induce VCAM-1 expression. Five nanomolars
of [18F]FB-cAbVCAM-1–5 was incubated during 1.5 h at 378C. After re-
moval of unbound tracer, the bound fraction was collected and counted
in a gamma-counter (Canberra-Packard, Downers Grove, IL, USA).
Non-stimulated cells were used as negative control. Competition bind-
ing studies with a 300-fold molar excess of unlabelled Nb were per-
formed to show the specificity of the binding. Experiments were
performed in triplicate. The results were normalized to the TNFa-
negative condition.
Animal model
The animal study protocol was approved by the ethical committee for
animal research of the Vrije Universiteit Brussel. Female (5-week-old)
ApoE2/2 mice (Charles-River, L’Arbresle, France) were fed a Western
diet (D12108C, Research Diets, New Brunswick, NJ, USA) for 21–25
weeks to induce atherosclerotic lesions. Lesions develop all along the
aorta, but are most prevalent in the region of the ascending aorta and
aortic arch. Female healthy control C57Bl/6 mice (Charles-River)
were used as control mice and remained on a standard chow diet.
Ex vivo biodistribution and atherosclerotic
lesion uptake
ApoE2/2 mice (n ¼ 6) and C57Bl/6 (n ¼ 6) control mice were injected
intravenously with [18F]FB-cAbVCAM-1–5 Nb (5–10 mg/7.1+
1.7 MBq). To demonstrate the specific uptake of the Nb, additional
ApoE2/2 mice were injected with 18F-labelled non-targeting control
Nb ([18F]FB-cAbBCII-10)10 (n ¼ 6) or with 70-fold molar excess of un-
labelled cAbVCAM-1–5 Nb (n ¼ 6). Mice were sacrificed at 3 h post-
injection. Organs and tissues of interest were dissected, weighed and
counted against a standard of known activity. Tissue or organ uptake
was calculated and expressed as percentage of injected dose per gram
(%ID/g), corrected for decay. Additional biodistribution data in C57Bl/6
mice at earlier time points are added as Supplementary data.
To assess atherosclerotic lesion uptake, the aorta was dissected from
aortic root to iliac bifurcation and was cut into 8–10 segments. The seg-
ments were analysed on a microscope and a lesion-extension score was
given according to plaque content: (Score 0) no lesion, (Score 1) lesion
covering up to 30% of the segment, (Score 2) lesions covering 30–75%
of the segment, and (Score 3) lesions extending over the whole seg-
ment. Each segment was then weighed and counted for radioactivity
in the gamma-counter. Lesion-to-blood and lesion-to-heart ratios
were also determined. The ‘lesion’ and ‘control lesion’ were defined
as the aorta segment with lesions extending over the whole segment
length (Score 3) and aorta segment with no atherosclerosis develop-
ment (Score 0), respectively.
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In vivo imaging was performed on a FLEX Triumph II triple-modality sys-
tem (TriFoil Imaging, Chatsworth, CA 91311, USA). Four groups of an-
imals were scanned (n ¼ 3 per group): C57Bl/6 control mice, ApoE2/2
mice, ApoE2/2 mice injected with non-targeting control Nb, and
ApoE2/2 mice injected with 70-fold molar excess of unlabelled Nb.
One hundred and fifty minutes after tracer injection (4.68+
2.45 MBq), the animals were placed under general anaesthesia using
2–5% isoflurane, and a 30-min PET scan was acquired. The PET images
were reconstructed into a 200 × 200 × 63 matrix by a 2D maximum
likelihood expectation maximization (MLEM) algorithm (LabPET Ver-
sion 1.12.1, TriFoil Imaging, Chatsworth, CA, USA) using 60 iterations
and a voxel size of 0.5 × 0.5 × 1.175 mm3 (x, y, z). Each PET scan was
followed by a CT scan using the following acquisition parameters: 256
projections, detector pixel size 50 mm, tube voltage 75 kV, tube current
500 mA, and field of view 90 mm. CT images were analytically recon-
structed using the filtered back projection reconstruction software of
the scanner (Cobra Version 7.3.4, Exxim Computing Corporation, Plea-
santon, CA, USA) into a 256 × 256 × 512 matrix with 200 mm isotrop-
ic voxel size. Each resultant CT image was inherently co-registered with
the corresponding PET scan.
Image analysis was performed using AMIDE imaging software. For
quantification of the PET signal, regions of interest (ROIs) were drawn
at the level of the ascending aorta and aortic arch (region with most ex-
tensive atherosclerotic lesion development) based on anatomical CT
imaging. Mean standardized uptake values (SUV) were used to compare
aortic uptake.
Statistical analysis
Data are expressed as mean+ standard deviation. Variables were
tested for homogeneity of variance by the Levene test. Comparisons be-
tween groups were performed using the one-way ANOVA tests with
corrections for multiple comparisons. Correlations between variables
were evaluated using the Spearman correlation coefficient. A P-value
of ,0.05 was considered significant. Statistical analysis was done using
SPSS Statistics software (version 22.0.0, IBM Company, Chicago, IL,
USA).
Results
18F -Radiolabelling of cAbVCAM-1–5
nanobody
As direct 18F-fluorination methods of proteins are difficult, the first
step in 18F-radiolabelling of cAbVCAM-1–5 Nb was the synthesis of
the prosthetic group [18F]-SFB. [18F]-SFB was radiosynthesized and
purified with 55+ 5% yield and a radiochemical purity of .95%.
After the radiolabeling reaction with cAbVCAM-1–5 Nb and puri-
fication, [18F]FB-anti-VCAM-1 Nb was obtained with a radiochem-
ical purity of .99% (Figure 1A and B). The chemical identity of
[18F]FB-cAbVCAMb1–5 was confirmed by comparison of the
gamma-trace with the UV-profile of the non-radioactive
cAbVCAM-1–5 Nb on RP-HPLC. The radiolabelled compound
was stable in PBS over a period of at least 3 h with .98% intact
[18F]FB-cAbVCAM-1–5 Nb (Figure 1C). Both in vitro and in vivo,
the 18F-labelled Nb showed minimal binding to serum proteins
and was not degraded (Figure 1D and E). Conversely,
[18F]FB-cAbVCAM-1–5 was metabolized in the kidneys, and meta-
bolites are excreted in the urine (Figure 1F).
In vitro assessment of functionality and
specificity
To assess the functionality and specificity of [18F]FB-cAbVCAM-1–
5, cell-binding studies on VCAM-1 expressing bEND5 cells and
VCAM-1-negative bEND5 cells were performed. To demonstrate
that the binding was receptor-specific, a 300-fold excess of un-
labelled cAbVCAM-1–5 Nb was added to VCAM-1-positive cells.
The results showed that the binding of [18F]FB-cAbVCAM-1–5
was receptor-mediated and could be inhibited by receptor satur-
ation (Figure 2).
Biodistribution
A summary of the biodistribution data for [18F]FB-cAbVCAM-1–5
in ApoE2/2 and C57Bl/6 mice at 3 h post-injection is presented in
Table 1. These data show that 18F-labelled Nbs were rapidly cleared
from circulation due to their fast renal clearance. An uptake of
,0.5% ID/g was observed in all other tissues and organs, except
for the spleen (1.76+ 0.76 and 1.88+ 0.34%ID/g in ApoE2/2
and C57Bl/6, respectively), an organ known to express VCAM-1
constitutively.10 This splenic uptake was not observed in the pres-
ence of an excess of cold cAbVCAM-1–5 or for [18F]FB
-cAbBCII10.
Uptake in atherosclerotic lesions
In ApoE2/2 mice, [18F]FB-cAbVCAM-1–5 uptake in excised aorta
segments with Score 1 (1.18+ 0.36%ID/g), Score 2 (1.49+
0.37%ID/g) and 3 (1.61+0.41%ID/g) was significantly higher com-
pared with segments with Score 0 (0.68+ 0.16%ID/g, P ¼ 0.001),
compared with the uptake in aorta segments of control mice
(0.52+0.20%ID/g, P, 0.0001), and compared with the uptake of
the non-targeting [18F]FB-cAbBCII10 Nb in segments of all scores
(Score 3: 0.33+ 0.09%ID/g, P, 0.0001) ((Figure 3). Co-injection
of a 70-fold excess of unlabelled cAbVCAM-1–5 Nb in ApoE2/2
mice resulted in a significant decrease in aortic uptake to the base-
line level (Score 3: 0.78+ 0.27%ID/g, P ¼ 0.001) (Figure 3). More-
over, [18F]FB-cAbVCAM-1–5 uptake in aorta segments of
ApoE2/2 mice correlated with the lesion-extension index (Spear-
man’s r2 ¼ 0.675, P, 0.0001). Fast blood clearance and low myo-
cardial uptake of the Nb resulted in high lesion-to-blood,
lesion-to-heart, and lesion-to-control vessel ratios (3.3+ 0.4,
12.4+ 0.4, and 3.1+0.6, respectively).
PET/CT imaging
In accordance with the ex vivo biodistribution data, PET/CT images
revealed for both 18F-labelled Nbs high signals in the kidneys and the
bladder. Signals in other organs and tissues were very low. Analysis
of transversal, coronal, and sagittal PET/CT images showed accumu-
lation of [18F]FB-cAbVCAM-1–5 at the level of ascending aorta and
aortic arch of ApoE2/2 mice, the region where most of the seg-
ments are scored as 3, while only background signals were observed
for the control groups (Figure 4A). Hence, quantification of the mean
SUV in this region revealed this difference was significant
(P, 0.0001) (Figure 4B). Lesions along the abdominal aorta could
not be identified due to the high renal activity.
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In the present study, we have described the development and valid-
ation of a new PET tracer specific for VCAM-1, and we demon-
strated the non-invasive PET/CT imaging of VCAM-1 expression
in atherosclerotic plaques in a murine model. This may represent
an attractive tool for clinical translation of imaging inflamed athero-
sclerotic plaques in patients.
Recently, we have reported the selection of the lead compound
cAbVCAM-1–5 with nanomolar affinity for mouse and human
VCAM-1 based on the screening of 10 Nbs derived from
heavy-chain-only antibodies raised in an immunized dromedary.10
Figure 1 Evaluation of radiochemical purity, stability and metabolization of the [18F]FB-cAbVCAM-1–5 tracer by RP-HPLC analysis (A and C)
and SEC analysis (B and D–F). (A and B) [18F]FB-cAbVCAM-1–5 elutes as a single peak without the presence of free 18F or unreacted 18F-SFB
[gamma-trace, tR ¼ 12.5 (RP-HPLC) and 8 min (SEC)]. (C and D) In vitro stability of [18F]FB-cAbVCAM-1–5 after 3 h, respectively, in PBS (.98%)
and serum (.98%). (E) In vivo stability in serum 5 min after injection. (F) Urine sample 30 min after injection showing metabolization of
[18F]FB-cAbVCAM-1–5. (Blue: Absorbance at 280 nm representing serum proteins, black: radioactive signal.)
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This compound was labelled with 99mTc for SPECT imaging of ath-
erosclerotic lesions in ApoE2/2 mice and it was shown that the up-
take of 99mTc-cAbVCAM-1–5 correlated with the level of VCAM-1
expression in these lesions.11 Moreover, SPECT/CT imaging with
this tracer was used to monitor the anti-inflammatory effects of sta-
tins.11 In the current study, cAbVCAM-1–5 Nb was radiolabelled
with 18F, often referred to as the ‘radionuclide of choice’ for PET im-
aging. Compared with other imaging modalities, PET is currently the
preferred clinical modality because it is the most sensitive and quan-
titative clinical molecular imaging technology. This feature is particu-
larly important for the detection of molecular markers of
atherosclerotic plaques where targets are commonly small and
sparse.
Essential characteristics of a radiotracer for clinical translation are
purity and stability, high specificity and affinity for the target, and fast
blood clearance to reach high target-to-background ratios.
18F-radiolabelled cAbVCAM-1–5 Nb was obtained with high radio-
chemical purity and remained stable and functional, both in vitro and
in vivo. Atherosclerotic lesions located in the region of the ascending
aorta and aortic arch of ApoE2/2 mice were specifically identified
by PET/CT imaging. To assure minimal background values in tissues
such as blood and myocardium, imaging was performed at 2–3 h
after injection, a time frame feasible for 18F-labelled probes. These
findings make the [18F]FB-cAbVCAM-1–5 Nb a quite attractive
tracer for human imaging.
Nanobodies labelled with radiometals such as 99mTc typically
show intense kidney retention in the proximal tubuli of the kidney
Figure 2 In vitro cell-binding studies. Specific binding of 5 nM
[18F]FB-cAbVCAM-1–5 Nb to VCAM-1 positive, TNF-a stimu-
lated bEND5 cells. This binding was significantly higher than bind-
ing to non-stimulated cells and it was specific, as it could be
blocked by an excess of unlabelled Nb. Data are presented as
mean+ SD. *P, 0.0001 TNF-a stimulated bEND5 cells vs. non-
stimulated cells and vs. blocking condition
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Ex-vivo biodistribution data of [18F]-FB-cAbVCAM-1–5 and [18F]-FB-cAbBCII-10 Nb 3 h after injection in
C57Bl/6 and ApoE2/2 mice
18F-cAbVCAM-1–5 18F-cAbVCAM-1–5/ blocking 18F-cAbBCII-10 P-values
ApoE2/2 C57Bl/6 ApoE2/2 ApoE2/2
Blood 0.48+0.20 0.41+0.03 0.52+0.17 0.31+0.16 NS
Liver 0.39+0.16a,b 0.28+0.03 0.22+0.06 0.13+0.03 aP ¼ 0.048
bP ¼ 0.010
Spleen 1.76+0.76a,b 1.88+0.34 0.47+0.06 0.11+0.03 aP ¼ 0.009
bP ¼ 0.003
Pancreas 0.17+0.07 0.14+0.13 0.16+0.04 0.18+0.06 NS
Kidneys 27.84+12.83b,c 3.33+0.74 21.52+6.3 40.64+15.90 cP, 0.0001
bP ¼ 0.042
Stomach 0.22+0.12 0.13+0.03 0.18+0.07 0.25+0.17 NS
Small intestines 0.21+0.11 0.19+0.05 0.14+0.04 0.14+0.11 NS
Large intestines 0.17+0.07 0.13+0.05 0.13+0.02 0.09+0.03 NS
Heart 0.13+0.04 0.18+0.05 0.13+0.03 0.09+0.03 NS
Lungs 0.44+0.30b 0.60+0.18 0.39+0.11 0.20+0.07 bP ¼ 0.038
Thymus 0.28+0.08a,b,c 0.19+0.05 0.17+0.07 0.11+0.03 cP ¼ 0.021
aP ¼ 0.004
bP, 0.0001
Muscle 0.08+0.05 0.07+0.03 0.07+0.02 0.06+0.04 NS
Bone 0.19+0.07b 0.22+0.06 0.16+0.06 0.13+0.06 bP ¼ 0.04
Lymph nodes 0.27+0.10a,b 0.19+0.06 0.16+0.06 0.13+0.06 aP ¼ 0.016
bP ¼ 0.003
Salivary gland 0.16+0.10 0.13+0.03 0.12+0.03 0.08+0.03 NS
Fat 0.08+0.05 0.08+0.05 0.12+0.04 0.07+0.06 NS
Data are expressed as mean %ID/g+ SD.
a18F-cAbVCAM-1–5 in ApoE2/2 vs. 18F-cAbVCAM-1–5/ blocking in ApoE2/2.
b18F-cAbVCAM-1–5 in ApoE2/2 vs. 18F-cAbBCII-10 in ApoE2/2.
c18F-cAbVCAM-1–5 in ApoE2/2 vs. 18F-cAbVCAM-1–5 in C57Bl/6.
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cortex by a mechanism that is at least partially mediated by the
megalin-receptor system.24 Remarkably, the kidney retention of
[18F]FB-cAbVCAM-1–5 was much lower compared with
99mTc-cAbVCAM-1–5 Nb (27.84+ 12.83 vs. 222+ 12%ID/g).
This can be explained by renal metabolization of the 18F-labelled tra-
cer and excretion of the metabolites via the urine. Furthermore, a
higher uptake of 99mTc-cAbVCAM-1–5 Nb is observed in organs
with constitutive VCAM-1 expression such as spleen, thymus, lymph
nodes, and bone marrow, compared with [18F]FB-cAbVCAM-1–5
[e.g. spleen (1.76+ 0.76 vs. 9.2+ 1.0%ID/g), thymus (0.28+ 0.08
vs. 1.7+0.1% ID/g)]. We speculate that these differences are partly
due to different specific activities of the tracers next to different bio-
physical and chemical properties of the radiolabelled compounds in
vivo. Nevertheless, comparable lesion-to-blood and lesion-to-heart
ratios were observed.
The abundant presence of macrophages is a hallmark feature of po-
tential vulnerable plaques.25 Over the past decade, there has been in-
creasing interest in the development of molecular imaging methods
capable of imaging the extent of plaque inflammation that could
potentially provide powerful predictive information on future cardio-
vascular events.26 VCAM-1 expression has been most preferentially
studied because of its function to recruit inflammatory cells to the
arterial intima and because its expression pattern could reflect the
degree of plaque inflammation.6 Indeed, several molecular imaging
strategies targeting VCAM-1 in the context of atherosclerosis have
been demonstrated using ultrasound,27,28 magnetic resonance,29 op-
tica,l30 or nuclear imaging.10,31 To this purpose, Nahrendorf et al. have
previously developed a multimeric peptide-based tracer, 18F-4V, for
PET/CT imaging of VCAM-1 expression. Comparable results with
the present study were obtained in terms of lesion-to-normal vessels,
lesion-to-blood, and lesion-to-myocardium ratios.
Besides the anti-VCAM-1 Nb presented in this study, many other
Nb-based tracers have been developed and validated in preclinical
models for the imaging of a variety of specific disease-related bio-
markers.32 They have been successfully labelled with different radio-
isotopes (68Ga, 99mTc, 18F, 111In),12,33 near infrared dyes,34
microbubbles,35 or gadolinium vesicles36 allowing their use for mul-
tiple imaging modalities such as SPECT, PET, optical imaging, ultra-
sound, or MRI. The Nb technology represents thus a versatile tool
for molecular imaging with great potential for clinical applications.
Hence, a Phase I clinical trial has been finalized successfully regarding
the application of a 68Ga-labelled HER2-specific Nb as PET tracer to
screen breast cancer patients for HER2 expression.17 Moreover,
preparations for a Phase I clinical trial with cAbVCAM-1–5 Nb
have already been initiated as the current tracer is being produced
complying with Good Manufacturing Practice (GMP) requirements.
In clinical research 18F-FDG has been widely used for imaging of
plaque inflammation in carotid lesions.37 However, coronary artery
imaging remains extremely challenging due to high myocardial back-
ground that is generally greater than any signal originating from a pla-
que. The low myocardial uptake of [18F]FB-cAbVCAM-1–5 Nb with
a high lesion-to-myocardium ratio renders it a promising tracer for
potential molecular imaging of coronary atherosclerosis in pa-
tients. Indeed, the feasibility of coronary molecular imaging in pa-
tients using PET/CT has already been shown using 18F-sodium
fluoride (18F-NaF) as a tracer of active microcalcification in athero-
sclerotic plaques38 or 18F-FLT, a thymine analogue accumulating
in proliferating cells.20 However, further studies are needed to
evaluate the impact of these findings on patient management and
treatment.
Study limitations
The present approach of PET/CT imaging of VCAM-1 expression
requests some considerations. The majority of thrombotic events
in culprit lesions are caused by plaque rupture.25 These plaques
show typically intensive infiltration of inflammatory cells. However,
Figure 3 Uptake in aorta segments according to the lesion-extension score. Aortic uptake in ApoE2/2 mice (n ¼ 6) injected with
[18F]FB-cAbVCAM-1–5 (n ¼ 6), [18F]FB-cAbVCAM-1–5 + blocking (n ¼ 6) and [18F]-FB-cAbBCII-10 (n ¼ 6) Nb and in C57Bl/6 mice (n ¼ 6)
injected with [18F]-FB-cAbVCAM-1–5. Uptake of [18F]FB-cAbVCAM-1–5 vs. blocking (*), vs. control Nb (#) and vs. aorta control mice (†).
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20–30% of coronary thrombi evolve from plaques that do not have
a large lipid core or significant inflammation but have superficial
endothelial erosions.3 This subset of high-risk plaques might be
missed by the current method.
In this study, we were able to visualize plaque inflammation in a mur-
ine model of atherosclerosis. However, atherosclerotic lesions of mur-
ine models differ from human pathology. [18F]FB-cAbVCAM-1–5 Nb
imaging of plaque inflammation in human coronary and carotid arteries
remains to be further investigated.
Conclusion
The present study demonstrates a sensitive and specific method for
non-invasive PET/CT imaging of VCAM-1 expression within athero-
sclerotic lesions, which may provide important information to char-
acterize atherosclerotic plaque inflammation. This preclinical
validation study holds the potential to be translated in patients. Fur-
ther clinical studies are needed to put this technology a step forward
in our quest for imaging potential vulnerable plaques.
Supplementary data
Supplementary data are available at European Heart Journal –
Cardiovascular Imaging online.
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Figure 4 PET/CT imaging in ApoE2/2 and C57Bl/6 mice. (A) Representative PET/CT images of ApoE2/2 and C57Bl/6 mice 2–3 h after injec-
tion of the radiotracer. Focal uptake of [18F]-FB-cAbVCAM-1–5 Nb is visible at the level of the ascending aorta and aortic arch in ApoE2/2 mice,
while background uptake is observed in C57Bl/6 control mice and in ApoE2/2 mice injected with control Nb. This focal uptake is specific as it
could be blocked by an excess of unlabelled Nb. (B) Quantification of PET signal at the level of aortic arch as the mean SUV (n ¼ 3 per group). Data
expressed as mean+ SD. *P, 0.0001 [18F]-FB-cAbVCAM-1–5 in ApoE2/2 mice vs. blocking experiments, vs. control Nb and vs. control
animals.
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